Analysis of COVID-19 mortality in patients with comorbidities in Côte d'Ivoire

Rui Usui; Shogo Kanamori; Maki Aomori; Setsuko Watabe

doi:10.4081/jphia.2022.1748

Analysis of COVID-19 mortality in patients with comorbidities in Côte d'Ivoire

J Public Health Afr. 2022 Oct 25;13(3):1748. doi: 10.4081/jphia.2022.1748. eCollection 2022 Sep 7.

Authors

Rui Usui^{1

2}, Shogo Kanamori³, Maki Aomori¹, Setsuko Watabe¹

Affiliations

¹ Department of Nursing, Graduate School of Medicine, The Yokohama City University, Yokohama, Kanagawa, Japan.
² Department of Critical and Invasive-Palliative Care Nursing, Graduate School of Health Care Sciences, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan.
³ Department of Community and Global Health, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.

Abstract

Background: Although COVID-19 has spread in Côte d'Ivoire, there is no report that summarizes the comorbidities of COVID-19 death cases.

Objective: To verify the types and prevalence of commodities associated with recorded COVID-19 deaths compared with the general adult population in Côte d'Ivoire.

Methods: Data on the comorbidities of COVID-19 deaths and the country's disease structure were collected from official government reports and WHO's reports.

Results: Among 67 patients studied, the biggest age group was 60-69 years old with 23 people (34%). Fifty-four patients (81%) had non-communicable diseases (NCDs) as comorbidities. The prevalence ratio between COVID-19 deaths and general adult population was 8.96 [95% Confidence Interval: 6.86-11.68] for diabetes, 1.74 [1.27-2.37] for hypertension, and 2.16 [1.32-3.51] for obesity.

Conclusions: To reduce the risk of death from COVID-19 in Côte d'Ivoire, focused infection prevention measures for elderly and diabetic patients are needed.

Keywords: COVID19 comorbidity; Côte d’Ivoire; non-communicable disease.

Grants and funding

Funding: This work was supported by the Japan Society for the Promotion of Science KAKENHI (Grants-in-Aid for Scientific Research) Grant Number JP1 9 K 1 9 7 6 8.